NCI: Breast Cancer Cases Could Rise by 50 Percent

A National Cancer Institute model forecasts a marked increase in estrogen receptor-positive tumors among older women by 2030.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, NCIAs the population of the U.S. grows and the average citizen lives longer, the total number of breast cancer cases among American women could be as much as 50 percent greater in 2030 than it was in 2011, according to a new forecast by the National Cancer Institute (NCI). NCI biostatistician Philip Rosenberg presented the findings yesterday (April 20) at the annual meeting of the American Association for Cancer Research (AACR) being held in Philadelphia.

Rosenberg explained that he NCI model predicts that the proportion of estrogen receptor (ER)-positive, in-situ breast cancer may rise from 19 percent to 29 percent, while rates of ER-negative breast cancer diagnoses will plateau or decrease. “Our estimate is that the total number of diagnoses of breast cancer in the U.S. will increase by about 50 percent by 2030,” he said during a press conference announcing the results. “The one silver lining is that we expect fewer ER-negative tumors, which include the most difficult-to-treat HER2-positive and triple-negative subtypes,” Rosenberg added in a statement.

The total number of new breast cancer cases in the U.S. will likely increase from 283,000 in 2011 to 441,000 in 2030, according to the NCI model, which incorporated data from the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Bob Grant

    From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo